Former U.S. Surgeon General will help guide Eko’s mission to expand access to AI-powered cardiac screening and early detection worldwide
SAN FRANCISCO, Aug. 21, 2025 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary detection, today announced that Jerome Adams, MD, MPH, FASA, former U.S. Surgeon General, board-certified anesthesiologist, and Executive Director of the Center for Community Health Enhancement and Learning at Purdue University, has joined the company as a Distinguished Medical Advisor. Dr. Adams brings decades of clinical, public health, and policy leadership to Eko at a time of accelerated company growth and a national focus on proactive, community-based early detection of cardiovascular disease.
“I’m proud to join Eko at a pivotal moment for both the company and our broader healthcare system,” said Dr. Jerome Adams. “Eko is transforming how we detect cardiovascular disease—making cutting-edge, AI-powered tools accessible to frontline providers in the communities that need them most. This is how we close gaps in care, improve outcomes, and ultimately save lives.”
During his tenure as Surgeon General, Dr. Adams issued influential advisories on maternal health and hypertension—two of the most pressing drivers of poor cardiovascular outcomes, particularly in underserved communities. These focus areas directly align with Eko’s mission to bring early, AI-powered detection tools to the frontlines of care, where timely intervention can have the greatest impact. He also issued key guidance on the opioid epidemic and the connection between community health and economic prosperity. A frequent national media contributor, Dr. Adams remains a vocal advocate for diversity, equity, and inclusion as essential pillars of public health.
In his role with Eko, Dr. Adams will provide strategic guidance on clinical implementation, product development, and public health partnerships. He will also advise on efforts to bring affordable, high-performance cardiac screening to everyday care, making earlier and more accurate detection possible in primary care settings that have not traditionally had access to specialist-level tools.
“Dr. Adams brings an exceptional combination of clinical insight, government leadership, and public health experience,” said Connor Landgraf, CEO and Co-Founder of Eko Health. “He knows how to turn medical innovation into real-world impact, and his perspective on expanding access, efficiency, and quality of care will be invaluable as we build on one of the largest deployments of AI-enabled medical devices in the world to reach even more clinicians and patients.”
In addition to his administrative role at Purdue, Dr. Adams is a Distinguished Professor of Practice in Pharmacy Practice and Public Health. During his tenure as Surgeon General, he issued influential advisories on naloxone and the opioid epidemic, maternal health, hypertension control, and the link between community health and economic prosperity. A frequent national media contributor, he is a vocal advocate for diversity, equity, and inclusion as public health imperatives.
With Dr. Adams’s expertise, Eko is deepening its focus on clinical excellence and expanding health equity on a global scale. Recent research highlights the potential value of Eko’s technology in enabling earlier detection of congenital heart disease in low-resource settings, ensuring children with life-threatening conditions receive timely care. In Nigeria, a randomized controlled trial published in Nature Medicine demonstrated the platform’s ability to improve detection of peripartum cardiomyopathy among pregnant women. In the United States, Eko’s collaboration with HeartSense is expanding access to structural heart disease detection in underserved communities, giving providers actionable insights that can change the course of a patient’s care.
About Eko Health
Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes & ECG devices, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with over 650,000 devices sold to providers globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California.
For more information about Eko Health, visit ekohealth.com.
Media Contact:
Sam Moore
Eko Health
[email protected]
©2025 Eko Health, Inc. All rights reserved. MKT-0003919
SOURCE Eko Health
